明德生物
(002932)
| 流通市值：30.55亿 | | | 总市值：45.50亿 |
| 流通股本：1.56亿 | | | 总股本：2.33亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 749,536,774.56 | 625,927,735.1 | 537,560,328.28 | 372,402,234.89 |
| 营业收入 | 749,536,774.56 | 625,927,735.1 | 537,560,328.28 | 372,402,234.89 |
| 二、营业总成本 | 720,146,379.19 | 561,146,420.11 | 453,350,326.35 | 305,499,408.61 |
| 营业成本 | 342,703,065.78 | 323,722,711.42 | 279,967,879.54 | 208,216,190.63 |
| 税金及附加 | 2,250,211.6 | 2,639,157.62 | 2,292,751.17 | 1,795,220.47 |
| 销售费用 | 115,945,141.24 | 115,480,326.24 | 82,102,414.45 | 45,958,031.73 |
| 管理费用 | 112,638,453.08 | 78,327,387.2 | 52,310,388.24 | 28,131,259.82 |
| 研发费用 | 141,415,136.54 | 106,632,983.58 | 71,934,069.91 | 33,184,792.04 |
| 财务费用 | 5,194,370.95 | -65,656,145.95 | -35,257,176.96 | -11,786,086.08 |
| 其中:利息费用 | 10,498,964.25 | 1,175,585.38 | 2,463,656.91 | - |
| 其中:利息收入 | 4,385,909.12 | -71,203,568.43 | 36,360,230.89 | - |
| 加:公允价值变动收益 | 4,589,114.71 | - | - | - |
| 加:投资收益 | 120,550,338.17 | 29,667,866.77 | 29,277,065.4 | 22,229,018.9 |
| 资产处置收益 | 307,817.69 | -413,203.59 | -269,106.33 | - |
| 资产减值损失(新) | 4,753,258.38 | 36,330,410.36 | - | - |
| 信用减值损失(新) | -79,952,184.94 | 71,819,897.76 | 43,869,573.05 | 2,724,573.46 |
| 其他收益 | 65,555,715.56 | 17,161,518.59 | 13,574,923.74 | 5,921,923.74 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 145,194,454.94 | 219,347,804.88 | 170,662,457.79 | 97,778,342.38 |
| 加:营业外收入 | 877,517.01 | 447,091.84 | 220,707.78 | 52,983.8 |
| 减:营业外支出 | 6,182,489.5 | 5,602,944.61 | 4,210,212.31 | 1,933,491.79 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 139,889,482.45 | 214,191,952.11 | 166,672,953.26 | 95,897,834.39 |
| 减:所得税费用 | 70,673,084.48 | 31,528,544.43 | 24,670,997.86 | 14,442,025.95 |
| 六、净利润 | 69,216,397.97 | 182,663,407.68 | 142,001,955.4 | 81,455,808.44 |
| 持续经营净利润 | 69,216,397.97 | 182,663,407.68 | 142,001,955.4 | 81,455,808.44 |
| 归属于母公司股东的净利润 | 74,925,916.55 | 145,299,822.2 | 112,572,471.06 | 75,450,691.09 |
| 少数股东损益 | -5,709,518.58 | 37,363,585.48 | 29,429,484.34 | 6,005,117.35 |
| (一)基本每股收益 | 0.33 | 0.63 | 0.49 | 0.49 |
| (二)稀释每股收益 | 0.33 | 0.63 | 0.48 | 0.48 |
| 八、其他综合收益 | - | - | 3,722,200 | - |
| 归属于母公司股东的其他综合收益 | - | - | 3,722,200 | - |
| 九、综合收益总额 | 69,216,397.97 | 182,663,407.68 | 145,724,155.4 | 81,455,808.44 |
| 归属于母公司股东的综合收益总额 | 74,925,916.55 | 145,299,822.2 | 116,294,671.06 | 75,450,691.09 |
| 归属于少数股东的综合收益总额 | -5,709,518.58 | 37,363,585.48 | 29,429,484.34 | 6,005,117.35 |
| 公告日期 | 2024-04-26 | 2023-10-31 | 2023-08-31 | 2023-04-27 |
| 审计意见(境内) | 标准无保留意见 | | | |